Methylphenidate in the treatment of amphetamine dependence: a double-blind randomised, placebo-controlled trial

Not Applicable

Completed

• Conditions: Amphetamine dependence; Mental and Behavioural Disorders

• Registration Number: ISRCTN54619615
• Lead Sponsor: niversity of Kuopio (Finland)

Brief Summary

2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17202560 Interim results

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-13
• Study Completion: 2009-12-31
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Amphetamine (or methamphetamine) dependence (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition [DSM-IV])
2. Aged between 18 - 65 years, either sex
3. Recent and accustomed amphetamine (methamphetamine) use (urine analysis positive)

Exclusion Criteria

Current exclusion criteria as of 24/04/2008:
1. Simultaneous participation in other treatment (intervention) studies
2. Uncontrolled use of other substances (e.g. alcohol) requiring medical treatment
3. Some other substance than amphetamine/methamphetamine as the primary drug
4. Another significant mental disorder or risk of suicide
5. Mental disorder which needs special treatment
6. Significant brain, thyroid, renal, gastrointestinal or cardiovascular disease
7. Epilepsy
8. Glaucoma
9. Tourette disorder or tics
10. Clinically significant liver disease
11. Female gender without adequate pregnancy prevention
12. Pregnancy
13. Previous methylphenidate abuse

Previous exclusion criteria:
1. Simultaneous participation in other treatment (intervention) studies
2. Having other native language than Finnish
3. Uncontrolled use of other substances (e.g. alcohol) requiring medical treatment
4. Some other substance than amphetamine/methamphetamine as the primary drug
5. Another significant mental disorder or risk of suicide
6. Mental disorder which needs special treatment
7. Significant brain, thyroid, renal, gastrointestinal or cardiovascular disease
8. Epilepsy
9. Glaucoma
10. Tourette disorder or tics
11. Clinically significant liver disease
12. Female gender without adequate pregnancy prevention
13. Pregnancy
14. Previous methylphenidate abuse

Study & Design

• Study Type: Interventional
• Study Design: Not specified